CD27 and non-small cell lung carcinoma: The results from this study showed that doxorubicin, mitoxantrone, irinotecan may have inhibitory effects on CD27 and PD1 based on the CMap pharmacogenomic profiles [54], with potential implications in combined use with NSCLC immunotherapy.